BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 31303176)

  • 1. Elimination of onchocerciasis in Africa by 2025: the need for a broad perspective.
    Cupp E; Sauerbrey M; Cama V; Eberhard M; Lammie PJ; Unnasch TR
    Infect Dis Poverty; 2019 Jul; 8(1):50. PubMed ID: 31303176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The positive influence the Onchocerciasis Elimination Program for the Americas has had on Africa programs.
    Richards FO; Nwoke BEB; Zarroug I; Tukahebwa E; Negussu N; Higazi TB; Oguttu D; Tadesse Z; Miri E; Aziz N; Habomugisha P; Katabarwa M
    Infect Dis Poverty; 2019 Jul; 8(1):52. PubMed ID: 31303175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The need for evidence-based strategies and tools for onchocerciasis elimination in Africa.
    Dadzie Y; Amazigo UV; Boatin BA; Sékétéli A
    Infect Dis Poverty; 2019 Jul; 8(1):62. PubMed ID: 31303174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elimination of onchocerciasis from Colombia: first proof of concept of river blindness elimination in the world.
    Nicholls RS; Duque S; Olaya LA; López MC; Sánchez SB; Morales AL; Palma GI
    Parasit Vectors; 2018 Apr; 11(1):237. PubMed ID: 29642939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is onchocerciasis elimination in Africa feasible by 2025: a perspective based on lessons learnt from the African control programmes.
    Dadzie Y; Amazigo UV; Boatin BA; Sékétéli A
    Infect Dis Poverty; 2018 Jul; 7(1):63. PubMed ID: 29966535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progress towards eliminating onchocerciasis in the WHO Region of the Americas: verification of elimination of transmission in Guatemala.
    Wkly Epidemiol Rec; 2016 Oct; 91(43):501-5. PubMed ID: 27801556
    [No Abstract]   [Full Text] [Related]  

  • 7. Onchocerciasis: shifting the target from control to elimination requires a new first-step-elimination mapping.
    Rebollo MP; Zoure H; Ogoussan K; Sodahlon Y; Ottesen EA; Cantey PT
    Int Health; 2018 Mar; 10(suppl_1):i14-i19. PubMed ID: 29471341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Onchocerciasis Elimination Program for the Americas (OEPA).
    Sauerbrey M
    Ann Trop Med Parasitol; 2008 Sep; 102 Suppl 1():25-9. PubMed ID: 18718151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elimination of human onchocerciasis: history of progress and current feasibility using ivermectin (Mectizan(®)) monotherapy.
    Cupp EW; Sauerbrey M; Richards F
    Acta Trop; 2011 Sep; 120 Suppl 1():S100-8. PubMed ID: 20801094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reaching the last mile: main challenges relating to and recommendations to accelerate onchocerciasis elimination in Africa.
    Gebrezgabiher G; Mekonnen Z; Yewhalaw D; Hailu A
    Infect Dis Poverty; 2019 Jul; 8(1):60. PubMed ID: 31269966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elimination of transmission of onchocerciasis (river blindness) with long-term ivermectin mass drug administration with or without vector control in sub-Saharan Africa: a systematic review and meta-analysis.
    Mutono N; Basáñez MG; James A; Stolk WA; Makori A; Kimani TN; Hollingsworth TD; Vasconcelos A; Dixon MA; de Vlas SJ; Thumbi SM
    Lancet Glob Health; 2024 May; 12(5):e771-e782. PubMed ID: 38484745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Feasibility of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: first evidence from studies in Mali and Senegal.
    Diawara L; Traoré MO; Badji A; Bissan Y; Doumbia K; Goita SF; Konaté L; Mounkoro K; Sarr MD; Seck AF; Toé L; Tourée S; Remme JH
    PLoS Negl Trop Dis; 2009 Jul; 3(7):e497. PubMed ID: 19621091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. River blindness.
    Unnasch TR
    Lancet; 2002 Jul; 360(9328):182-3. PubMed ID: 12133647
    [No Abstract]   [Full Text] [Related]  

  • 14. Onchocerca volvulus infection and serological prevalence, ocular onchocerciasis and parasite transmission in northern and central Togo after decades of Simulium damnosum s.l. vector control and mass drug administration of ivermectin.
    Komlan K; Vossberg PS; Gantin RG; Solim T; Korbmacher F; Banla M; Padjoudoum K; Karabou P; Köhler C; Soboslay PT
    PLoS Negl Trop Dis; 2018 Mar; 12(3):e0006312. PubMed ID: 29494606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ten years of NGDO action against river blindness.
    Drameh PS; Richards FO; Cross C; Etya'alé DE; Kassalow JS
    Trends Parasitol; 2002 Sep; 18(9):378-80. PubMed ID: 12377246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Macrofilaricidal Efficacy of Repeated Doses of Ivermectin for the Treatment of River Blindness.
    Walker M; Pion SDS; Fang H; Gardon J; Kamgno J; Basáñez MG; Boussinesq M
    Clin Infect Dis; 2017 Nov; 65(12):2026-2034. PubMed ID: 29020189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elimination of onchocerciasis in Ecuador: findings of post-treatment surveillance.
    Guevara Á; Lovato R; Proaño R; Rodriguez-Perez MA; Unnasch T; Cooper PJ; Guderian RH
    Parasit Vectors; 2018 Apr; 11(1):265. PubMed ID: 29690907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. From river blindness control to elimination: bridge over troubled water.
    Colebunders R; Basáñez MG; Siling K; Post RJ; Rotsaert A; Mmbando B; Suykerbuyk P; Hopkins A
    Infect Dis Poverty; 2018 Mar; 7(1):21. PubMed ID: 29587844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progress toward elimination of onchocerciasis in the Americas.
    Sauerbrey M; Rakers LJ; Richards FO
    Int Health; 2018 Mar; 10(suppl_1):i71-i78. PubMed ID: 29471334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Towards the elimination of onchocerciasis.
    Thylefors B; Alleman M
    Ann Trop Med Parasitol; 2006 Dec; 100(8):733-46. PubMed ID: 17227651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.